retatrutide glp-1 gip glucagon receptor agonist (Eli Lilly's triple GLP-1/GIP/Glucagon agonist) just delivered the most impressive obesity + osteoarthritis data we've ever seen in the phase 3 TRIUMPH-4 trial: Retatrutide 10mg — Triple Receptor

It works the same way mechanistically, activating the GLP-1 receptor to reduce appetite, slow gastric emptying and improve insulin sensitivity, but the small molecule structure means it can be taken orally with fewer absorption constraints. In trials, orforglipron lowered blood sugar and produced meaningful weight loss in people with obesity and in those with type 2 diabetes, says LaValle

The results of phase 2 (dose-ranging) trials with primary endpoints of HbA 1c change (Rosenstock et al, 2023) and body-weight change (Jastreboff et al, 2023) are shown in Table 6

Cyanocobalamin is the most widely used form of vitamin B12, and has hematopoietic activity apparently identical to that of the antianemia factor in purified liver extract

Glutathione, on the other hand, is flexible

Standard semaglutide titration: Weeks 1-4: 0.25 mg weekly Weeks 5-8: 0.5 mg weekly Weeks 9-12: 1.0 mg weekly Week 13+: 1.7 mg or 2.4 mg weekly (target dose) Hashimoto's-adjusted approach: Weeks 1-6: 0.25 mg weekly (extended to allow thyroid monitoring at week 6) Weeks 7-12: 0.5 mg weekly (TSH check before increasing) Weeks 13-16: 1.0 mg weekly Week 17+: Assess whether higher doses are needed The extended timeline allows for thyroid function checks at each step, ensuring levothyroxine doses are adjusted proactively rather than reactively